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The procedure is also associated with a high number of visits to outpatient clinics and the emergency department (ED) for complications, which increases health care resource utilisation and procedural costs. 2 The number of G-tube procedures is increasing annually in the United States, with an average increase of 0.15 procedures per year (Slope 0.50), from 10 procedures per 100 000 patients in 1997 to 11.9 procedures per 100 000 patients in 2009. 3 As the postoperative care of the G-tube in paediatric patients is usually the responsibility of the parents, the increase in the number of procedures has led to considerable familial burden in addition to increased health care costs to treat complications. 3 Hypergranulation tissue formation is the most common G-tube complication, seen in 44%-68% of patients. 1, 2, 4, 5 Hypergranulation tissue is excessive, vascularised scar tissue that builds up in response to chronic irritation within a wound during the early granulation and epithelialisation stages of wound healing. It can lead to bleeding from the wound site, chronic skin breakdown, and leaking of feeds and gastric acid onto skin and clothing. The treatment of hypergranulation tissue complications includes chemical cautery with silver nitrate, polyurethane foam, laser ablation, washcloth abrasion, and topical corticosteroids. 6 A hydrocolloid dressing (HD) is recommended during the granulation and epithelialisation stages of wound healing. [7] [8] [9] HD is a non-occlusive polyester mesh containing carboxymethylcellulose particles and petrolatum. HD is non-adherent, painless to change or remove, and rapidly absorbs wound exudate. 8 A recent change to standard HD is the addition of silver sulphate, impregnated into the HD mesh (Silver HD). The silver ions are bactericidal, inducing bacterial DNA replication errors that lead to cell death. 10, 11 The silver ions are not absorbed into the wound tissue, and there is no systemic absorption of silver from the dressing. More rapid wound healing has been demonstrated in open-label randomised trials of silver HD compared with standard HD. 12 While HD and silver HD are often used to treat wounds and have been shown to reduce hypergranulation tissue after it develops, the effect of these dressings on the prevention of hypergranulation tissue has not been previously studied. We conducted a prospective, randomised study to compare the effect of (1) standard G-tube care, (2) standard HD treatment, and (3) silver HD treatment after G-tube placement in children on the postoperative formation of hypergranulation tissue, tube dislodgement, infection, and ED use. We hypothesised that silver HD would reduce the incidence of G-tube-associated postoperative hypergranulation tissue development by 50% compared with standard G-tube care.
| METHODS

| Study participants
We performed a prospective, randomised study to compare the effects of standard care and treatment with standard HD or silver HD on preventing postoperative G-tube complications. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in the approval given by the institutional review board of the Ann & Robert H. Lurie Children's Hospital of Chicago. Informed consent was obtained from the parent or legal authorised representative of each participant prior to enrolment.
Children were eligible for enrollment if they were between 1 month and 17 years of age and underwent G-tube placement by a paediatric surgeon from January 2011 to November 2016. Children less than 30 days of age or children with mothers who were pregnant or breastfeeding were excluded. Silver sulphate-impregnated hydrocolloid has not been studied in children under 30 days of life or in mothers who are pregnant or breastfeeding. Additional exclusion criteria were patients who underwent G-tube placement by gastroenterology or interventional radiology at the same institution. A sample size of 171 patients (57 in each arm) was calculated using a power of 0.8 and a significance level of 0.05, predicting a possible 5% loss to follow up.
| Randomisation
Children were randomised by random number generator for digits at least three numerals in length. The final digit of the random number was used for assignment. A last number of 1-3 was assigned to standard care, 4-6 was assigned to HD, and 7-9 was assigned to silver HD. Any number ending in zero was removed from the random number list.
| Intervention
Patients were randomly assigned to one of the three groups: (1) standard postoperative G-tube care, (2) standard HD G-tube wound treatment, or (3) silver HD G-tube wound treatment, all of which are considered standard of care. Dressings were provided free of charge by Halyard Health (Alpharetta, Georgia). For patients assigned to HD or silver HD, the dressing was placed around the G-tube on postoperative day 1, at the time of parent education in the proper use and care of the G-tube. Parents were instructed to change the dressing once every 2 days and to continue for a total of 30 days. At the end of the 30-day study period, parents were instructed on routine G-tube care, including daily washing with soap and water.
| Follow up and study outcomes
De-identified data were collected from the medical record, including patient demographics, comorbidities, operative
Key Messages
• in this study, we analysed the use of hydrocolloid dressings in the prevention of hypergranulation tissue formation after gastrostomy tube (G-tube) placement in children
• we proved if prevention treatment with hydrocolloid standard or silver-impregnated dressings decreases the formation of hypergranulation tissue compared with standard care
• the sample included 128 children who underwent G-tube placement of the patients, 69.5% developed hypergranulation tissue during the postoperative period, with no significant differences in incidence among the three treatment arms; hydrocolloid dressings (standard or silver impregnated) do not prevent the development of hypergranulation tissue after Gtube placement in paediatric patients technique, postoperative complications, and treatment assignment. Patients were routinely seen for a postoperative visit 2 weeks after G-tube placement, where they were assessed for the presence or absence of hypergranulation tissue, tube dislodgment, and infection. Visits to the ED for Gtube-related complications were also noted. If no complications occurred, the next visit was scheduled for 3 months later for the first G-tube change. Additional visits were performed as needed for complications or routine G-tube evaluations.
| Statistical analysis
The χ 2 test and t-test were used to compare differences in outcomes between the three treatment groups. A P value < 0.05 was considered statistically significant. Data were analysed in SAS 9.3.
| RESULTS
A total of 171 patients were enrolled. Forty-three (25%) patients were excluded; 22 were lost to follow up, 12 did not meet the inclusion criteria, 6 had incomplete data, and 3 died during the study, leaving 128 (75%) patients for subsequent analyses ( Figure 1 ). The study cohort had a median age of 1.5 years (range: 0-18.5 years; Table 1 and 20 to silver HD, with an overall incidence of 69%, 63%, and 76%, respectively. There was no difference among the three treatment arms in the incidence of hypergranulation tissue at the three different time points analysed: (1) <30 days after G-tube placement (standard care, HD, or silver HD); (2) >30 days after G-tube placement (routine care); and (3) 0-120 days (entire study period; Table 3 ). Among the patients who developed hypergranulation tissue, 13 (14.6%) had recurrent hypergranulation tissue during the study period. Seven (54%) patients had more than one episode, and six had a single episode. The average time to the first recurrence was 10 weeks. Of the patients who developed hypergranulation tissue, 46 of 89 visited the ED (56%), while only 6 of 39 patients without hypergranulation tissue visited the ED (19%). Of all patients who visited the ED, 80% were for complications related to the G-tube, while the remainder were for unrelated causes (Table 4) .
| DISCUSSION
In our study population, hypergranulation tissue was the most common complication in patients after a G-tube placement. These data are consistent with numerous other studies. 1, 2, 4, 5 The use of HDs, either standard or silver-impregnated, did not prevent the development of hypergranulation tissue after G-tube placement. The prevalence of hypergranulation tissue during the study was higher compared with previous studies (69.5% versus 44-68%; 1,2,4,5). The increased incidence is likely secondary to increased vigilance for the occurrence of hypergranulation tissue relative to the study objectives. As prospective studies are more accurate tools for data collection, 13 the true incidence in this study was therefore expected to be higher than the majority of published data. While the prevalence of hypergranulation tissue was slightly lower in the intervention study period (30% early occurrence versus 40% late occurrence), this difference was not associated with any of the study interventions. Complications related to the Gtube were the most common cause of visits to the ED among this population of children. In addition to hypergranulation tissue, tube dislodgment and infection of the surgical site were also very common. Saavedra et al. previously reported tube dislodgment as the most common G-tube-related complaint in the ED (62% of study participants 14 ). Our data demonstrate a lower, but equally concerning, rate of tube dislodgement.
Current treatment for hypergranulation tissue has no established gold standard. Multiple treatments have been used, including topical corticosteroids, chemical cautery with silver nitrate, polyurethane foam, laser ablation, and washcloth abrasion. 6, 15 More recently, the use of salt (Hypertonic environment 16 ) has been demonstrated to be effective in reducing oedematous hypergranulation tissue; this inexpensive and uncomplicated approach is reproducible in a home environment if required. Moody et al. showed successful resolution of hypergranulation tissue in four adult patients by combining HD dressing with pulsed dye laser but not with either treatment alone. 17 The lack of clearly defined guidelines for the treatment of hypergranulation tissue combined with a high incidence and significant health care and familial burden make the prevention of hypergranulation tissue a prime target for interventional studies. Unfortunately, in the current study, we were unable to prevent the appearance of hypergranulation tissue with early application of HDs (standard or silver-impregnated) immediately after G-tube placement. These data suggest that neither excess fluid nor local skin irritation from the tube is involved in the pathogenesis of hypergranulation tissue formation after G-tube placement.
There are limitations related to the interpretation and application of the findings from this study. First, the study was powered for a total of 171 patients, assuming a 5% loss to follow up. The loss to follow up was far higher in this study. However, given the overall higher incidence of hypergranulation tissue compared with that reported in previous studies, we do not believe that the high loss to follow up changed the negative results of the study. Second, we did not assess adherence to hydrocolloid (standard or silverimpregnated) beyond the 2-week postop check. Finally, because of limited to supplies of the product for use in the study, we were not able to continue the use of the HDs (standard and silver-impregnated) beyond the 30-day intervention period. As the rate of hypergranulation tissue was not different between assigned groups for either intervention, it is unlikely that an extension of the study period would have changed the results of the study.
| CONCLUSION
Gastrostomy-related postoperative hypergranulation tissue is a significant concern in the paediatric population. HDs (standard or silver-impregnated) did not prevent the postoperative development of hypergranulation tissue after G-tube placement. Future studies should examine approaches to prevent G-tube complications such as hypergranulation tissue development and reduce the associated clinical and economic burdens for patients and caregivers.
